相关实验视频
Updated: Jan 10, 2026

09:36
Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
816
葡萄糖保护RINm5Fβ细胞免受诱导的亡作用
Rosa Isela Ortiz-Huidobro1, Pablo Pánico1, Ana María Salazar1
1Department of Genomic Medicine and Environmental Toxicology, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Scientific reports
|November 25, 2025
概括
高血糖水平在2型糖尿病 (T2D) 研究中减轻了诱导的β细胞亡. 这项研究揭示了葡萄糖联合治疗会改变胰岛素信号通路,影响细胞生存机制.
科学领域:
- 内分泌学 在内分泌学.
- 毒理学 毒理学 毒理学
- 细胞生物学 细胞生物学
背景情况:
- 2型糖尿病 (T2D) 涉及高血糖,β细胞功能障碍和胰岛素抵抗.
- 暴露和高碳水化合物摄入量是T2D风险因素,但它们的相互作用机制尚不清楚.
- 了解这些相互作用对于阐明β细胞亡途径至关重要.
研究的目的:
- 为了研究和葡萄糖对β细胞亡的影响.
- 探索涉及胰岛素信号通路的潜在机制.
- 为了确定葡萄糖联合治疗是否会影响诱导的β细胞亡.
主要方法:
- 在实验室中,RINm5F胰岛素瘤β细胞被 (As),葡萄糖 (Gluc) 和它们的组合 (As + Gluc) 暴露48小时和72小时.
- 使用流细胞测量和关键信号通路 (PI3K/Akt,MAPK) 的评估来分析亡.
- 测量calpain活性和Bax/Caspase-3通路标记物.
主要成果:
- 单独诱导β细胞的早期亡.
- 葡萄糖的联合治疗减少了引起的亡.
- As + Gluc改变了胰岛素信号传递,增加了Akt/S6K1的激活,减少了ERK1/2的激活.
- 与As + Gluc相比,与单独As相比,观察到增加了calpain活性和Bax/Caspase-3通路的下调.
结论:
- 葡萄糖的联合治疗减轻了β细胞中的亲亡作用.
- 卡尔帕因在这种保护性反应中发挥着重要作用.
- Akt/S6K1信号轴发生了显著的变化,这表明它参与了对毒性的保护机制.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
566
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
566
Hormones Regulating Blood Glucose
6.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.4K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509
Oral Hypoglycemic Agents: Glinides
573
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
573
Hypoglycemia and Glucagon
779
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
779

